Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr;42(4):822-836.
doi: 10.1002/nau.25167. Epub 2023 Mar 6.

Sacral neuromodulation in the management of chronic pelvic pain: A systematic review and meta-analysis

Julian Greig  1 , Quentin Mak  1 , Marc A Furrer  2   3 , Arun Sahai  2 , Nicholas Raison  2   4
Affiliations
Free article
Meta-Analysis

Sacral neuromodulation in the management of chronic pelvic pain: A systematic review and meta-analysis

Julian Greig et al. Neurourol Urodyn. 2023 Apr.
Free article

Abstract

Introduction: Sacral neuromodulation (SNM) is a treatment approved for use in several conditions including refractory overactive bladder (OAB) and voiding dysfunction. Chronic pelvic pain (CPP) is a debilitating condition for which treatment is often challenging. SNM shows promising effect in patients with refractory CPP. However, there is a lack of clear evidence, especially in long-term outcomes. This systematic review will assess outcomes of SNM for treating CPP.

Methods: A systematic search of MEDLINE, Embase, Cochrane Central and clinical trial databases was completed from database inception until January 14, 2022. Studies using original data investigating SNM in an adult population with CPP which recorded pre and posttreatment pain scores were selected. Primary outcome was numerical change in pain score. Secondary outcomes were quality of life assessment and change in medication use and all-time complications of SNM. Risk of bias was assessed using the Newcastle Ottawa Tool for cohort studies.

Results: Twenty-six of 1026 identified articles were selected evaluating 853 patients with CPP. The implantation rate after test-phase success was 64.3%. Significant improvement of pain scores was reported in 13 studies; three studies reported no significant change. WMD in pain scores on a 10-point scale was -4.64 (95% confidence interval [CI] = -5.32 to -3.95, p < 0.00001) across 20 studies which were quantitatively synthesized: effects were maintained at long-term follow-up. Mean follow-up was 42.5 months (0-59). Quality of life was measured by RAND SF-36 and EQ-5D questionnaires and all studies reported improvement in quality of life. One hundred and eighty-nine complications were reported in 1555 patients (Clavien-Dindo Grade I-IIIb). Risk of bias ranged from low to high risk. Studies were case series and bias stemmed from selection bias and loss to follow-up.

Conclusion: Sacral Neuromodulation is a reasonably effective treatment of Chronic Pelvic Pain and significantly reduces pain and increases patients' quality of life with immediate to long-term effects.

Keywords: interstitial cystitis; nerve stimulation; neuromodulation; pelvic pain; sacral nerve.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Royal College of Obstetricians and Gynaecologists. Initial Management of Chronic Pelvic Pain (Green-top Guideline No. 41); 2012. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_41.pdf
    1. Zondervan KT, Yudkin PL, Vessey MP, et al. The community prevalence of chronic pelvic pain in women and associated illness behaviour. Br J Gen Pract. 2001;51(468):541-547.
    1. Till SR, As-Sanie S, Schrepf A. Psychology of chronic pelvic pain: prevalence, neurobiological vulnerabilities, and treatment. Clin Obstet Gynaecol. 2019;62(1):22.
    1. European Association of Urology. Guidelines on Chronic Pelvic Pain. European Association of Urology; 2015.
    1. Mahran A, Baaklini G, Hassani D, et al. Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature. Int Urogynecol J. 2019;30(7):1023-1035. doi:10.1007/s00192-019-03898-w